

Overexpression of GSTP1 promotes colorectal cancer cell proliferation, invasion and metastasis by up-regulating STAT3

Feifei Wang

Southern Medical University

Ceng Zhang

Southern Medical University

Xiaohui Zhu

Southern Medical University

Dan Zhang

Southern Medical University

Zhaowen Zhang

Southern Medical University

Shunjie Ni

Southern Medical University

Zhizhi Wang

Southern Medical University

Shuyi Xu

Southern Medical University

Xiaoliang Lan

Southern Medical University

Yanqing Ding

Southern Medical University

Li Liang (✉ lli@fimmu.com)

Southern Medical University <https://orcid.org/0000-0001-5302-2754>

Research Article

Keywords: GSTP1, STAT3, CRC, proliferation, invasion, metastasis

Posted Date: March 19th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-315672/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Overexpression of GSTP1 promotes colorectal cancer cell**
2 **proliferation, invasion and metastasis by up-regulating STAT3**

3 **Running title: GSTP1 promotes colorectal cancer progression by upregulating**
4 **STAT3**

5 Feifei Wang^{1,2△}, Ceng Zhang^{1,2△}, Xiaohui Zhu^{1,2△}, Dan Zhang^{1,2}, Zhaowen Zhang^{1,2},
6 Shunjie Ni³, Zhizhi Wang⁴, Shuyi Xu⁵, Xiaoliang Lan⁶, Yanqing Ding^{1,2}, Li Liang^{1,2*}

7 **Authors' affiliations:**

8 1 Department of Pathology, Nanfang Hospital and Basic Medical College, Southern
9 Medical University, Guangzhou 510515, Guangdong Province, People's Republic
10 of China.

11 2 Guangdong Province Key Laboratory of Molecular Tumor Pathology, Guangzhou
12 510515, Guangdong province, People's Republic of China.

13 3 Department of Neurology, Nanfang Hospital, Southern Medical University,
14 Guangzhou 510515, Guangdong province, People's Republic of China.

15 4 Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University,
16 Guangzhou 510515, Guangdong province, People's Republic of China.

17 5 Basic Medical College, Southern Medical University, Guangzhou 510515,
18 Guangdong Province, People's Republic of China.

19 6 Department of General Surgery, Nanfang Hospital, Southern Medical University,
20 Guangzhou 510515, Guangdong Province, People's Republic of China.

21 * **Correspondence to:** Li Liang, Department of Pathology, Nanfang Hospital and
22 Basic Medical College, Guangdong Province Key Laboratory of Molecular Tumor

23 Pathology, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou
24 510515, People's Republic of China. Email:lli@fimmu.com. Phone: 86-20-61642148
25 Fax: 86-20-61648224. ORCID:0000-0001-5302-2754.

26 Δ : FF Wang, C Zhang and XH Zhu, contributed equally to this work.

27 **Abstract**

28 Abnormal expression of glutathione S-transferase Pi 1 (GSTP1) is associated with
29 the progression of several tumor types. However, its role and molecular mechanism in
30 the progression of colorectal cancer (CRC) is largely unknown. In the present study,
31 immunohistochemistry (IHC) and quantitative-reverse transcription PCR (qRT-PCR)
32 were used to detect the expression of GSTP1 and signal transducer and activator of
33 transcription 3 (STAT3) in CRC tissues. Western blotting was applied to detect the
34 expression of GSTP1 and proteins of Janus kinase (JAK)-STAT3 pathway. The
35 interaction and co-localization of GSTP1 and STAT3 were detected by
36 co-immunoprecipitation (CO-IP) and immunofluorescence, respectively. A positive
37 correlation was identified between the expression of GSTP1 and STAT3 in human
38 CRC tissues. Overexpression of GSTP1 promoted the proliferation, invasion and
39 metastasis of CRC cells by upregulating STAT3. GSTP1 and STAT3 can directly bind
40 to and regulate each other, and can be regulated by the upstream gene which was
41 called F-box only protein 8 (FBX8). The present study demonstrated that GSTP1
42 could enhance the expression of STAT3 to promote the proliferation, invasion and
43 metastasis of CRC cells, which provides a potential therapeutic target for clinical
44 treatment of CRC.

45 **Keywords**

46 GSTP1; STAT3, CRC; proliferation; invasion; metastasis

47

48 **1. Background**

49 Following the lung and breast cancer, CRC is the third most common cancer
50 worldwide [1]. The combined application of surgery, chemotherapy and radiotherapy
51 can control many localized tumors, however, it is limited in the restriction of the
52 development of metastatic disease [2]. Therefore, further elucidation of the molecular
53 mechanisms underlying the tumorigenesis and pathogenesis of CRC is urgently
54 required for this lethal disease.

55 Glutathione S-transferases (GSTs) (EC 2.5.1.18) are phase II metabolic enzymes [3],
56 which play a role in xenobiotic biotransformation [4], drug metabolism [5], protection
57 against oxidative stress, and modulating cell proliferation and signaling pathways [6,
58 7]. The GST Pi 1 (GSTP1), as an isozyme of GST, is a major regulator of cell
59 signaling in response to stress, hypoxia, growth factors and other stimuli [8]. GSTP1
60 is overexpressed in a variety of human cancers, including gastric cancer, pancreatic
61 cancer and bladder cancer [9, 10]. GSTP1 is also involved in the process of
62 proliferation and invasion in tumor cells; The overexpression of GSTP1 promotes
63 tumor cell proliferation and inhibits apoptosis in head and neck squamous cell
64 carcinoma (HNSCC) [11]. However, GSTP1 inhibits the proliferation of bladder
65 cancer T24 cells and arrests these cells in the G0/G1 phase [12]. In addition, a recent
66 study suggested that GSTP1 may be applied as an important biomarker for liquid

67 biopsy [13].

68 The signal transducer and activator of transcription (STAT) family is phosphorylated
69 via Janus kinases (JAKs) in response to the binding of growth factors or cytokines to
70 their corresponding receptors [14-16]. These factors are known to stimulate the
71 activation of intracellular STAT proteins, which are phosphorylated and dimerized,
72 and subsequently translocated to the nucleus for transactivation of a number of genes
73 involved in numerous cellular processes [17]. Persistent activation of STAT3 has been
74 observed in multiple human malignancies, including various stages of CRC [18-20].
75 Furthermore, high expression of STAT3 alters the cell cycle [21, 22] and inhibits
76 apoptosis by upregulating anti-apoptotic signaling [23, 24] in inflammation-associated
77 CRC and other human cancers [25]. In addition, GSTP1 negatively regulates STAT3
78 activation in epidermal growth factor (EGF) signaling, and is also a regulator of the
79 cell cycle via EGF signaling in human hepatocellular carcinoma (HCC) [8]. However,
80 the regulatory mechanisms between GSTP1 and STAT3 in the progression of CRC
81 remain unknown.

82 In our previous studies, it was identified that the loss of F-box only protein 8
83 (FBX8) in hepatocellular carcinoma, gastric cancer and CRC was associated with
84 poor survival of patients [26-28]. FBX8 is a metastatic suppressor downstream of
85 miR-223 and targets mTOR degradation in CRC [27]. It was also found that FBX8
86 inhibits the proliferation, invasion and metastasis of CRC by promoting the
87 degradation of GSTP1. At the same time, it was confirmed that GSTP1 can be used as
88 an effective marker to predict the prognosis of CRC [29].

89 The present study revealed that overexpression of GSTP1 can promote the
90 proliferation, invasion and metastasis of CRC cells by upregulating STAT3, and this
91 function can be regulated by FBX8. Therefore, it may provide a potential therapeutic
92 target for the clinical treatment of CRC.

93

94 **2. Materials and methods**

95 *2.1 IHC*

96 The sections were dewaxed and rehydrated, the endogenous peroxidase was
97 eliminated with 3% H₂O₂. The antigen was repaired with 0.01 M, pH 6.0 sodium
98 citrate buffer by microwave oven boiling for 5 min. After blocking with 5% goat
99 serum at room temperature for 1 h, add anti-GSTP1(1:200) or anti-STAT3(1:100)
100 antibody which were diluted with appropriate proportion about 50 µl and overnight at
101 4°C. Incubating with horseradish egg protein rabbit secondary antibody or murine
102 secondary antibody for 90 min at room temperature. Labeling streptavidin with
103 appropriate horseradish peroxidase, incubate for 30 min at room temperature. DAB
104 color developer needs to be observed under the microscope.

105 Staining was scored in a double-blind manner by two individuals with a score of 0
106 (representative negative), 1 (weak), 2 (medium), and 3 (strong). Depending on the
107 percentage of the stained area relative to the total cancerous tissue area or blood
108 vessel, the staining range is divided into 0 points (0%), 1 point (1-25%), 2 points
109 (26-50%), 3 points (51-75%) and 4 points (76 -100%). the sum of the dyeing strength
110 and range was taken as the final dyeing value (0-7): (-) total score <3 points, (+) total

111 score 3 points, (++) total score 4 points, (+++) total score is 5 points or more, in
112 which - or + is a low expression group, ++ and +++ are high expression groups.

113 *2.2 Immunofluorescence*

114 For immunofluorescence of cells seeded at a density of 0.5×10^4 cells on Confocal
115 NEST dish glass bottom Petri dishes. After 24 h, cells were fixed in 4%
116 paraformaldehyde, permeabilized with 0.02% Triton-X/1 × PBS, and blocked in 1 ×
117 PBS + 10% fetal bovine serum and 1% BSA. Primary GSTP1 (1:200) and STAT3
118 (1:100) antibodies were incubated overnight at 4°C at the dilutions listed below in 1 ×
119 PBS. Secondary antibodies coupled to Alexa Fluor 488 or 594 (Invitrogen) was
120 incubated 2 h at room temperature. Nuclear DNA was stained with 4',
121 6-diamidino-2-phenylindole (DAPI). Confocal images were taken by Olympus
122 inverted fluorescence microscope and were outputted by PV10-ASW 1.7 viewer
123 software.

124 *2.3 Co-IP*

125 In brief, the extracts of SW620 cells were blocked with IgG or protein A/G-agarose
126 2 h at 4°C to get rid of unspecific protein binding and then they were incubated with
127 anti-FBX8 or anti-GSTP1 antibody overnight at 4°C. The protein A/G-agarose was
128 separated out by centrifugation at 4°C, 2500 rpm. PVDF membranes were blocked
129 with 5% skim milk 1 h at room temperature and incubated with GSTP1 (1:200) and
130 STAT3 (1:100) antibodies overnight at 4°C at the dilutions listed below in 5% skim
131 milk. Protein bands were visualized using enhanced chemiluminescence kit HRP (FD
132 bio-femto ECL Kit).

133 *2.4 Glutathione S-transferase (GST) pull-down assay*

134 The interaction of truncated GSTP1 with STAT3 was examined in HCT116 and
135 SW620 cells by GST-mediated pull-down assays (Thermo Scientific, Rockford, IL).
136 Recombinant GST-STAT3-CCD (218-400), GST-STAT3-DBD (401-564),
137 GST-STAT3-Linker (565-663) and GST-STAT3-SH2 (664-768) proteins were
138 expressed and purified. Purified GST-STAT3-CCD (218-400), GST-STAT3-DBD
139 (401-564), GST-STAT3-Linker (565-663) and GST-STAT3-SH2 (664-768) fragments
140 were bound to glutathione resin as a GST-fusion protein and incubated with GSTP1 at
141 4°C for 2 h. After extensive washing with assay buffer, the complex was eluted with 5
142 mM reduced glutathione and the bound protein complexes were disrupted. Then, the
143 proteins were separated on SDS-PAGE and Western blotting.

144 *2.5 Statistical analysis*

145 All statistical analyses were performed by SPSS version 22.0 (IBM, USA). The
146 results were presented as mean \pm SD. Pearson correlation analysis was applied to
147 analyze the correlation between GSTP1 and STAT3. For experiments among/between
148 sample groups or three comparisons were analyzed by one-way ANOVA or
149 independent samples T-test. Before the analysis of variance, Levene test was used for
150 variance. A two-tailed $P < 0.05$ was considered as statistically significant in all tests.

151 Detailed methods about Plasmids and siRNA transfection, Cell proliferation
152 assay(CCK8), Cell invasion assays in vitro, Western blotting, qRT-PCR analysis were
153 described in Appendix A-Supplementary data.

154

155 **3. Results**

156 **3.1 The expression levels of GSTP1 and STAT3 are positively correlated**
157 **in human CRC tissues**

158 STAT3, widely recognized as a cancer gene, is typically associated with poor
159 prognosis of various human malignancies and promotes cancer progression or
160 metastasis [30-33]. The direct interaction between GSTP1 and STAT3 can promote
161 HCC progression [8], and our previous study found that GSTP1 can be ubiquitinated
162 by FBX8, thus inhibiting its function in promoting CRC proliferation, invasion and
163 metastasis [29]. Therefore, IHC was used to detect the expression of GSTP1 and
164 STAT3 in 20 human CRC tissues. The results demonstrated that the expression levels
165 of GSTP1 and STAT3 in human CRC tissues were positively correlated (Figure 1A).
166 Western blotting and qRT-PCR were used to detect the expression levels of GSTP1
167 and STAT3 in 8 paired fresh CRC tissues (Figure 1B and 1C). As shown in (Figure
168 1D), the expression of GSTP1 was also positively correlated with STAT3 in paired
169 fresh CRC tissues (Pearson's $r = -0.8781$, $P = 0.0006$).

170

171 **3.2 Overexpression of GSTP1 promotes the proliferation, invasion and**
172 **metastasis of CRC cells dependent on STAT3**

173 The expression of GSTP1 is positively correlated with STAT3. Combined with
174 previous studies, we predicted GSTP1 may play a role in the progression of CRC by
175 regulating STAT3. CRC cell lines with stable knockdown of GSTP1 were used in the
176 previous study [29] (SW620/shGSTP1 and HCT116/shGSTP1 cell lines), and STAT3

177 was overexpressed in these cells to perform relevant recovery experiments. As shown
178 in (Figure 2A and 2B), overexpression of STAT3 could significantly promote the
179 invasion and proliferation of cells in the GSTP1-knockdown group in vitro. In
180 addition, the expression levels of STAT3 and GSTP1 were detected in subcutaneous
181 tumors, in situ implants and liver metastases of CRC in nude mice, which were
182 obtained from a previous study. The results demonstrated that in these three tumor
183 tissues, the expression of STAT3 was significantly upregulated in the GSTP1
184 overexpressed group (Figure 3A and 3B), which indicated that the expression of
185 GSTP1 and STAT3 in mice tissue samples are consistent.

186

187 3.3 GSTP1 and STAT3 can directly bind and regulate each other

188 It was further hypothesized that GSTP1 could interact with STAT3 in CRC cells. As
189 expected, Co-IP analyses and immunofluorescence identified the interaction between
190 the two proteins. The existence of GSTP1 was detected in the immunoprecipitates
191 obtained with an antibody against STAT3 (Figure 4A). Immunofluorescence
192 demonstrated that GSTP1 and STAT3 exhibited co-localization in the cytoplasm of
193 SW620 cells (Figure 4B). The present study cloned four truncated constructs of
194 STAT3: CCD (218-400), DBD (401-564), Linker (565-663) and SH2 (664-768)
195 (Figure 4C), and then identified an interaction between the CCD domain of STAT3
196 and GSTP1 by GST pull-down (Figure 4C). It was identified that the CCD domain of
197 STAT3 was essential for the interaction with GSTP1.

198 Thus, it was examined whether GSTP1 could activate the STAT3 signaling pathway

199 in CRC cells, and it was identified that exogenous expression of GSTP1 further
200 increased the protein expression of phosphorylated (p)-STAT3, STAT3 and the
201 downstream STAT3 targets cyclin D1 and CDC25A in SW480 cells (Figure 4D).
202 However, there was no appreciable effect on the upstream components of the STAT3
203 signaling pathway, such as JAK2 and p-JAK2 (Figure 4D). By contrast, depletion of
204 GSTP1 in SW620 cells decreased the levels of p-STAT3, STAT3, cyclin D1, and
205 CDC25A (Figure 4D). Notably, this regulation was not one-way; it was identified that
206 ectopic expression of STAT3 could also upregulate the protein level of GSTP1 and
207 induce higher levels of the downstream STAT3 targets cyclin D1 and CDC25A. At the
208 same time, silencing STAT3 could decrease the expression levels of GSTP1, cyclin
209 D1 and CDC25A, but not the expression of p-JAK2 (Figure 4E). In addition, when
210 AG490 (100 μ M) was used to block the JAK2-STAT3 pathway, a significant decrease
211 was observed in the expression of JAK2, p-JAK2, STAT3, p-STAT3 and GSTP1 24 h
212 after treating LoVo cells (Figure 4F).

213

214 3.4 The interaction between GSTP1 and STAT3 is regulated by FBX8

215 As a downstream target of FBX8, GSTP1 can interact with STAT3, therefore, we
216 predicted that FBX8 could regulate the interaction between GSTP1 and STAT3. Co-IP
217 assays demonstrated that the existence of GSTP1, in FBX8-expressing SW620 and
218 SW480/FBX8 cells, was detected to a higher extent in the immunoprecipitates
219 obtained with an antibody against STAT3 compared with the control cells (Figure 5A
220 and 5B). However, the presence of GSTP1 demonstrated the opposite results; it was

221 detected to a lesser extent in the immunoprecipitates obtained with an antibody
222 against STAT3 (Figure 5A and 5B). These results indicated that FBX8 was a
223 suppressive factor for the combination of GSTP1 and STAT3.

224

225 **4. Discussion**

226 Previously, we identified GSTP1 as the downstream target of FBX8 by Co-IP and
227 mass spectrometry analyses, and confirmed that GSTP1 can promote the proliferation,
228 invasion and metastasis of CRC [29]. In addition, it was identified that GSTP1 could
229 regulate STAT3 to affect the development of HCC [8]. Therefore, we hypothesized
230 that GSTP1 may be involved in the progression of CRC by regulating STAT3.

231 The present study detected GSTP1 and STAT3 in human colorectal tissues and found
232 that GSTP1 expression was positively correlated with STAT3 expression. This result
233 revealed that GSTP1 may be able to regulate the expression of STAT3 to play a role in
234 the progression of CRC. Recent evidence suggests GSTP1 is involved in tumor cell
235 proliferation and invasion; overexpression of GSTP1 increased cell proliferation in
236 HNSCC [11]. In comparison, GSTP1 arrests bladder cancer T24 cells in the G0/G1
237 phase and upregulates p21 expression [12]. The present study investigated the effect
238 of GSTP1 on the proliferation and invasion of CRC cells in vitro by recovery
239 experiments. The results demonstrated that overexpression of STAT3 could
240 significantly promote the proliferation and invasion of CRC cells after GSTP1
241 downregulation. This indicated that GSTP1 promoted the proliferation and invasion
242 of CRC cells depending on STAT3. In addition, the immunohistochemical results of

243 subcutaneous tumors, *in situ* implanted tumors and liver metastases of CRC in mice
244 also confirmed the aforementioned conclusion.

245 Mechanistically, the present studies served as a proof-of-concept that GSTP1 and
246 STAT3 can form a complex, and that upregulation of GSTP1 led to activation of the
247 STAT3 pathway (Figure 6). Meanwhile, STAT3 can positively regulate the protein
248 expression of GSTP1. STAT3 is phosphorylated via JAK, then dimerized and
249 subsequently translocated to the nucleus for transactivation of a number of genes
250 involved in numerous cellular processes [14-17]. In addition, the overexpression of
251 STAT3 can affect the cell cycle [21, 22] or inhibit apoptosis by enhancing
252 anti-apoptotic signaling [23, 24] in CRC. Therefore, identifying the association
253 between GSTP1 and the STAT3 pathway is an important way to illustrate the
254 molecular mechanisms of GSTP1 in CRC. The present results confirmed the
255 interaction of GSTP1 and STAT3, and demonstrated that GSTP1 positively regulated
256 STAT3 signaling, resulting in the alteration of p-STAT3 and STAT3, as well as the
257 targeted genes such as cyclin D1 and CDC25A. STAT3 siRNA significantly abolished
258 the increase of STAT3, cyclin D1 and CDC25A, and decreased the protein expression
259 of GSTP1, but there was no change in p-JAK2. Exogenous STAT3 exhibited the
260 adverse results. In addition, western blotting revealed a concentration-dependent
261 decrease in the level of JAK2, p-JAK2, STAT3, p-STAT3 and GSTP1 after 24 h of
262 treating LoVo cells with the specific inhibitor (AG490) of JAK2. These results
263 demonstrated GSTP1 interacted with STAT3 without involvement of JAK2.
264 Combined with previous research that FBX8 can degrade the expression of GSTP1

265 [29], we speculated that FBX8 could affect the association of GSTP1 and STAT3.
266 Subsequent experiments confirmed that FBX8 was a restraining factor for the
267 combination of GSTP1 and STAT3.

268

269 **5. Conclusions**

270 In summary, GSTP1, as the downstream effector of FBX8, was identified as an
271 important promoter and a useful prognostic marker for CRC. GSTP1 could interact
272 with STAT3 and upregulate the expression of STAT3, as well as its related
273 downstream molecules [34], to promote the proliferation, invasion and metastasis of
274 CRC. Therefore, the present study provided a potential new molecular target for the
275 treatment of CRC metastasis.

276

277 **List of abbreviations**

278 GSTP1 glutathione S-transferase Pi 1
279 CRC colorectal cancer
280 STAT3 signal transducer and activator of transcription 3
281 FBX8 F-box only protein 8
282 IHC immunohistochemistry
283 qRT-PCR reverse transcription-quantitative PCR
284 CO-IP co-immunoprecipitation

285

286 **Declaration of ethics approval and consent to participate**

287 Fresh CRC tissues were obtained from the department of pathology in nanfang
288 hospital, and prior approval was obtained from the Southern Medical University
289 Institutional Board (Guangzhou, China). Informed consent was obtained from each
290 patient. Animal studies were reviewed and approved by the Institutional Animal Care
291 and Use Committee of Southern Medical University.

292

293 **Declaration of availability of data and materials**

294 All data and models generated or used during the study appear in the submitted
295 article.

296

297 **Declaration of competing interests**

298 The authors declare that they have no competing interests.

299

300 **Funding**

301 This work was supported by the National Key R&D program of China (Grant
302 No.2017YFC1309002); National Natural Science Foundation of China (Grant
303 No.81672821; No.81872041; No.81802306; No.81903002); Project funded by China
304 Postdoctoral Science Foundation (Grant No.2018M643125; No.2019M652963);
305 Natural Science Foundation Key program of Guangdong Province of china (Grant
306 No.2018B0303110017); Natural Science Foundation of Guangdong Province of china
307 (Grant No.2019A1515011436).

308

309 **Authors' contributions**

310 Feifei Wang, Ceng Zhang, Xiaohui Zhu and Dan Zhang: Experiments. Shunjie Ni,
311 Zhizhi Wang and Professor Yanqing Ding: Statistical analysis. Zhaowen Zhang, Shuyi
312 Xu and Xiaoliang Lan: Collecting tissue samples. Professor Li Liang: Conceived
313 experiments. Analyzed data. Feifei Wang, Xiaohui Zhu and Li Liang: Writing the
314 paper. All authors read and approved the final manuscript.

315

316 **References**

- 317 [1] Parkin DM. Global cancer statistics in the year 2000. *The Lancet Oncology*.
318 2001; 2:533-543. [https://doi.org/10.1016/s1470-2045\(01\)00486-7](https://doi.org/10.1016/s1470-2045(01)00486-7).
- 319 [2] Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. *Nature*
320 *medicine*. 2006; 12:895-904. <https://doi.org/10.1038/nm1469>.
- 321 [3] Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, et al.
322 FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell
323 lymphomas. *Nature*. 2012; 481:90-93. <https://doi.org/10.1038/nature10688>.
- 324 [4] Jakoby WB. The glutathione S-transferases: a group of multifunctional
325 detoxification proteins. *Advances in enzymology and related areas of molecular*
326 *biology*. 1978; 46:383-414. <https://doi.org/10.1002/9780470122914.ch6>.
- 327 [5] Chasseaud LF. The role of glutathione and glutathione S-transferases in the
328 metabolism of chemical carcinogens and other electrophilic agents. *Advances in*
329 *cancer research*. 1979; 29:175-274. [https://doi.org/10.1016/s0065-230x\(08\)60848-9](https://doi.org/10.1016/s0065-230x(08)60848-9).
- 330 [6] Eaton DL, Bammler TK. Concise review of the glutathione S-transferases and
331 their significance to toxicology. *Toxicological sciences : an official journal of the*
332 *Society of Toxicology*. 1999; 49:156-164. <https://doi.org/10.1093/toxsci/49.2.156>.
- 333 [7] Townsend D, Tew K. Cancer drugs, genetic variation and the
334 glutathione-S-transferase gene family. *American journal of pharmacogenomics :*
335 *genomics-related research in drug development and clinical practice*. 2003;

336 3:157-172.<https://doi.org/10.2165/00129785-200303030-00002>.

337 [8] Kou X, Chen N, Feng Z, Luo L, Yin Z. GSTP1 negatively regulates Stat3
338 activation in epidermal growth factor signaling. *Oncology letters*. 5:1053-1057.
339 <https://doi.org/10.3892/ol.2012.1098>.

340 [9] Howells RE, Dhar KK, Hoban PR, Jones PW, Fryer AA, Redman CW, et al.
341 Association between glutathione-S-transferase GSTP1 genotypes, GSTP1
342 over-expression, and outcome in epithelial ovarian cancer. *International journal of*
343 *gynecological cancer : official journal of the International Gynecological Cancer*
344 *Society*. 2004; 14:242-250.<https://doi.org/10.1111/j.1048-891X.2004.014207.x>.

345 [10] Ruzza P, Rosato A, Rossi CR, Floreani M, Quintieri L. Glutathione transferases
346 as targets for cancer therapy. *Anti-cancer agents in medicinal chemistry*. 2009;
347 9:763-777. <https://doi.org/10.2174/187152009789056895>.

348 [11] Mutallip M, Nohata N, Hanazawa T, Kikkawa N, Horiguchi S, Fujimura L, et
349 al. Glutathione S-transferase P1 (GSTP1) suppresses cell apoptosis and its regulation
350 by miR-133 α in head and neck squamous cell carcinoma (HNSCC). *International*
351 *journal of molecular medicine*. 2011; 27:345-352.
352 <https://doi.org/10.3892/ijmm.2010.589>.

353 [12] Gao L, Fang YQ, Zhang TY, Ge B, Xu B, Huang JF, et al. GSTP1 arrests
354 bladder cancer T24 cells in G0/G1 phase and up-regulates p21 expression.
355 *International journal of clinical and experimental medicine*. 2014; 7:2984-2991.

356 [13] Gurioli G, Martignano F, Salvi S, Costantini M, Gunelli R, Casadio V. GSTP1
357 methylation in cancer: a liquid biopsy biomarker? *Clinical chemistry and laboratory*
358 *medicine*. 2018; 56:702-717.<https://doi.org/10.1515/cclm-2017-0703>.

359 [14] Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors
360 provides novel molecular targets for therapeutic intervention. *Clinical cancer research :*
361 *an official journal of the American Association for Cancer Research*. 2002;8:945-954.

362 [15] Quintás-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway:
363 mutations, inhibitors, and resistance. *Clinical cancer research : an official journal of*
364 *the American Association for Cancer Research*.

365 2013;19:1933-1940.<https://doi.org/10.1515/cclm-2017-0703>.

366 [16] Yu CL, Meyer DJ, Campbell GS, Lerner AC, Carter-Su C, Schwartz J, et al.
367 Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the
368 Src oncoprotein. Science (New York, NY). 1995;
369 269:81-83.<https://doi.org/10.1126/science.7541555>.

370 [17] Takeda K, Akira S. STAT family of transcription factors in cytokine-mediated
371 biological responses. Cytokine & growth factor reviews. 2000;
372 11:199-207.[https://doi.org/10.1016/s1359-6101\(00\)00005-8](https://doi.org/10.1016/s1359-6101(00)00005-8).

373 [18] Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al.
374 Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell
375 carcinogenesis in vivo. Proceedings of the National Academy of Sciences of the
376 United States of America. 2000;97:4227-4232.<https://doi.org/10.1073/pnas.97.8.4227>.

377 [19] Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3
378 oncogene product in human ovarian carcinoma cells. Gynecologic oncology. 2000;
379 79:67-73.<https://doi.org/10.1006/gyno.2000.5931>.

380 [20] Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ.
381 Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis
382 in glioblastoma multiforme cells. Oncogene. 2002;
383 21:8404-8413.<https://doi.org/10.1038/sj.onc.1206047>.

384 [21] Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, et al.
385 Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines:
386 inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon
387 carcinoma cells. The American journal of pathology. 2005; 167:969-980.
388 [https://doi.org/10.1016/s0002-9440\(10\)61187-x](https://doi.org/10.1016/s0002-9440(10)61187-x).

389 [22] Yu LZ, Wang HY, Yang SP, Yuan ZP, Xu FY, Sun C, et al. Expression of
390 interleukin-22/STAT3 signaling pathway in ulcerative colitis and related
391 carcinogenesis. World journal of gastroenterology. 2013; 19:2638-2649.
392 <https://doi.org/10.3748/wjg.v19.i17.2638>.

393 [23] Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, et al.
394 Persistent STAT3 activation in colon cancer is associated with enhanced cell

395 proliferation and tumor growth. *Neoplasia* (New York, NY). 2005; 7:545-555.
396 <https://doi.org/10.1593/neo.04571>.

397 [24] Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al.
398 Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in
399 growth regulation of human breast carcinoma cells. *Oncogene*. 2001; 20:2499-2513.
400 <https://doi.org/10.1038/sj.onc.1204349>.

401 [25] Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a
402 leading role for STAT3. *Nature reviews Cancer*. 2009; 9:798-809.
403 <https://doi.org/10.1038/nrc2734>.

404 [26] Wang F, Qiao Y, Yu J, Ren X, Wang J, Ding Y, et al. FBX8 Acts as an Invasion
405 and Metastasis Suppressor and Correlates with Poor Survival in Hepatocellular
406 Carcinoma. *PloS one*. 2013; 8:e65495. <https://doi.org/10.1371/journal.pone.0065495>.

407 [27] Wang FF, Zhang XJ, Yan YR, Zhu XH, Yu J, Ding Y, et al. FBX8 is a
408 metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in
409 colorectal carcinoma. *Cancer letters*. 2017; 388:85-95.
410 <https://doi.org/10.1016/j.canlet.2016.11.031>.

411 [28] Wu P, Wang F, Wang Y, Men H, Zhu X, He G, et al. Significance of FBX8 in
412 progression of gastric cancer. *Experimental and molecular pathology*. 2015;
413 98:360-366. <https://doi.org/10.1016/j.yexmp.2015.03.015>.

414 [29] FeiFei W, HongHai X, YongRong Y, PingXiang W, JianHua W, XiaoHui Z, et
415 al. FBX8 degrades GSTP1 through ubiquitination to suppress colorectal cancer
416 progression. *Cell death & disease*. 2019; 10:351.
417 <https://doi.org/10.1038/s41419-019-1588-z>.

418 [30] Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation
419 of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of
420 incidence and its association with pathological features and clinical outcome. *The*
421 *Journal of urology*. 2002;168:762-765.

422 [31] Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al.
423 Constitutive activation of signal transducers and activators of transcription 3
424 correlates with cyclin D1 overexpression and may provide a novel prognostic marker

425 in head and neck squamous cell carcinoma. *Cancer research*. 2002; 62:3351-3355.

426 [32] Kawada M, Seno H, Uenoyama Y, Sawabu T, Kanda N, Fukui H, et al. Signal
427 transducers and activators of transcription 3 activation is involved in nuclear
428 accumulation of beta-catenin in colorectal cancer. *Cancer research*. 2006;
429 66:2913-2917.<https://doi.org/10.1158/0008-5472.can-05-3460>.

430 [33] Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, et al.
431 STAT3 expression, molecular features, inflammation patterns, and prognosis in a
432 database of 724 colorectal cancers. *Clinical cancer research : an official journal of the*
433 *American Association for Cancer Research*. 2011; 17:1452-1462.
434 <https://doi.org/10.1158/1078-0432.ccr-10-2694>.

435 [34] Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors:
436 emerging opportunities and challenges. *Oncogene*. 2016; 35:939-951.
437 <https://doi.org/10.1038/onc.2015.150>.

438

439 **Figure 1. GSTP1 expression is positively correlated with the expression of STAT3**
440 **in human colorectal cancer tissues**

441 (A) The expression levels of GSTP1 and STAT3 in human CRC tissues were detected
442 by IHC. Scale bars represent 50 μm (left) and 20 μm (right). (B) Western blot analysis
443 was performed to detect the expression levels of GSTP1 and STAT3 in 8 paired fresh
444 tissue samples of human CRC. (C) The relative mRNA expression levels of GSTP1
445 and STAT3 in 8 paired fresh tissue samples of human CRC were detected by
446 qRT-PCR. All samples were tested in triplicate. Bars represent the mean \pm SD. (D)
447 The correlation analysis between GSTP1 and STAT3 was performed by Pearson's
448 correlation analysis (Pearson's $r = -0.8781$, $P = 0.0006$).

449 **Figure 2. Overexpression of STAT3 can reverse the inhibition of invasion and**
450 **proliferation induced by downregulating GSTP1**

451 (A) Effects of overexpression of STAT3 on SW620/shGSTP1 and HCT116/shGSTP1
452 cell invasion were detected by invasion assay. Scale bars represent 50 μ m. All samples
453 were analyzed in triplicate. Bars represent the mean \pm SD. *P<0.05, **P<0.01. (B)
454 Effects of overexpression of STAT3 on SW620/shGSTP1 and HCT116/shGSTP1 cell
455 proliferation were detected by CCK8 assay. All samples were tested in triplicate. Bars
456 represent the mean \pm SD. *P<0.05, **P<0.01.

457 **Figure 3. Overexpression of GSTP1 can upregulate the expression of STAT3 in**
458 **vivo**

459 (A) The expressions of GSTP1 and STAT3 in subcutaneous tumors of nude mice were
460 detected by immunohistochemistry. Scale bars represent 50 μ m (left) and 20 μ m
461 (right). (B) The expression of GSTP1 and STAT3 in orthotopic implantation of
462 colorectal tumors and liver metastases in nude mice were detected by
463 immunohistochemistry. Scale bars represent 50 μ m (left) and 20 μ m (right).

464 **Figure 4. GSTP1 and STAT3 can interact with each other**

465 (A) The interaction between GSTP1 and STAT3 was detected by a
466 co-immunoprecipitation assay with the SW620 cell line. (B) The co-location between
467 GSTP1 and STAT3 was detected by an immunofluorescence assay with the SW620
468 cell line. Scale bars represent 10 μ m. (C) The direct interaction site between GSTP1
469 and STAT3 was detected by a GST pull-down assay. (D) Western blot analysis was
470 performed to detect the expression of JAK/STAT3 signaling pathway-related proteins
471 in SW620/siGSTP1 and SW480/GSTP1 cell lines. (E) Western blot analysis was
472 performed to detect the expression of JAK/STAT3 signaling pathway-related proteins

473 in SW620/siSTAT3 and LoVo/STAT3 cell lines. **(F)** Western blot analysis was
474 performed to detect the expression of GSTP1 and JAK/STAT3 signaling
475 pathway-related proteins following AG490 treatment of LoVo cells.

476 **Figure 5. The interaction between GSTP1 and STAT3 is regulated by FBX8**

477 **(A)** The interaction between GSTP1 and STAT3 was detected by a CO-IP assay after
478 AG490 treatment of SW620 cells. **(B)** The interaction between GSTP1 and STAT3
479 was detected by a CO-IP assay with SW480/FBX8 cells.

480 **Figure 6. Schematic diagram of the role between GSTP1 and STAT3 in CRC**

Figures




Figure 1

GSTP1 expression is positively correlated with the expression of STAT3 in human colorectal cancer tissues (A) The expression levels of GSTP1 and STAT3 in human CRC tissues were detected by IHC. Scale bars represent 50 μm (left) and 20 μm (right). (B) Western blot analysis was performed to detect the expression levels of GSTP1 and STAT3 in 8 paired fresh tissue samples of human CRC. (C) The relative mRNA expression levels of GSTP1 and STAT3 in 8 paired fresh tissue samples of human CRC were detected by qRT-PCR. All samples were tested in triplicate. Bars represent the mean \pm SD. (D) The correlation analysis between GSTP1 and STAT3 was performed by Pearson's correlation analysis (Pearson's $r = -0.8781$, $P = 0.0006$).




Figure 2

Overexpression of STAT3 can reverse the inhibition of invasion and proliferation induced by downregulating GSTP1 (A) Effects of overexpression of STAT3 on SW620/shGSTP1 and HCT116/shGSTP1 cell invasion were detected by invasion assay. Scale bars represent 50 μm . All samples were analyzed in triplicate. Bars represent the mean \pm SD. * $P < 0.05$, ** $P < 0.01$. (B) Effects of overexpression of STAT3 on SW620/shGSTP1 and HCT116/shGSTP1 cell proliferation were detected by CCK8 assay. All samples were tested in triplicate. Bars represent the mean \pm SD. * $P < 0.05$, ** $P < 0.01$.




Figure 3

Overexpression of GSTP1 can upregulate the expression of STAT3 in vivo (A) The expressions of GSTP1 and STAT3 in subcutaneous tumors of nude mice were detected by immunohistochemistry. Scale bars represent 50 µm (left) and 20 µm (right). (B) The expression of GSTP1 and STAT3 in orthotopic implantation of colorectal tumors and liver metastases in nude mice were detected by immunohistochemistry. Scale bars represent 50 µm (left) and 20 µm (right).




Figure 4

GSTP1 and STAT3 can interact with each other (A) The interaction between GSTP1 and STAT3 was detected by a co-immunoprecipitation assay with the SW620 cell line. (B) The co-location between GSTP1 and STAT3 was detected by an immunofluorescence assay with the SW620 cell line. Scale bars represent 10 μm. (C) The direct interaction site between GSTP1 and STAT3 was detected by a GST pull-down assay. (D) Western blot analysis was performed to detect the expression of JAK/STAT3 signaling pathway-related proteins in SW620/siGSTP1 and SW480/GSTP1 cell lines. (E) Western blot analysis was performed to detect the expression of JAK/STAT3 signaling pathway-related proteins in SW620/siSTAT3 and LoVo/STAT3 cell lines. (F) Western blot analysis was performed to detect the expression of GSTP1 and JAK/STAT3 signaling pathway-related proteins following AG490 treatment of LoVo cells.




Figure 5

The interaction between GSTP1 and STAT3 is regulated by FBX8 (A) The interaction between GSTP1 and STAT3 was detected by a CO-IP assay after AG490 treatment of SW620 cells. (B) The interaction between GSTP1 and STAT3 was detected by a CO-IP assay with SW480/FBX8 cells.




Figure 6

Schematic diagram of the role between GSTP1 and STAT3 in CRC

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Attachment1.pdf](#)